Purpose of Session
To reinforce the importance of utilizing force field analysis
as a tool for implementing change
To present several models of client-clinic staff communications
To review the purpose and usage of asthma visit and treatment
plan forms by clinic staff and patients
| |
Key Concepts
Developing communication skills for teaching families with asthma
An understanding of the team approach to asthma management also involves good communication with the family of the child with asthma.
Therefore, when talking with the child or his or her caregiver, it is important to:
Pay
attention to nonverbal behaviors
Be
attentive to what the child and/or his/her caregiver is saying
Involve
the child in the conversation
Be
sure that the family understands the relevant information about
asthma and the treatment for the child that is being communicated
to them
| |
Handout 4-1 (Activity II)
[To be handed out by instructor]
| |
Handout 4-2 (Activity II)
1. What nonverbal behaviors did you observe and how did they
affect the interaction?
2. How did the doctor handle the family's concerns?
3. How was the child involved in the session?
4. What did the doctor teach the family about asthma? Do you
think the mother understood?
5. What were some other behaviors shown by the mother, child,
or doctor that strike you as being important for us to see? Why?
| |
Handout 4-3 (Activity II)
1. What nonverbal behaviors did you observe and how did they
affect the interaction?
2. How did the nurse handle the family's concerns?
3. How was the child involved in the session?
4. What did the nurse teach the family about asthma? Do you
think the mother understood?
5. Did you see any differences in the family's behavior with
the doctor and with the nurse? What were they?
| |
Handout 4-4 (Activity VIII)
First Visit for Asthma Form
| |
Handout 4-5 (Activity VIII)
Return Visit for Asthma Form
| |
Handout 4-6 (Activity VIII)
LONG TERM TREATMENT PLAN FOR MILD INTERMITTENT
ASTHMA
Name ________________ Date
___________ Spacer ____________
CLINICAL
CONDITION |
Baseline
Plan &
When asthma is under control |
At
the FIRST
sign of a cold
or mild attack |
For
rapidly worsening asthma
(severe attack) |
For cough
or wheeze with exercise |
Peak Flow
(% personal best) |
80% or above |
50 to 80% |
below 50% |
|
|
MEDICATION
Reliever:
Inhaled short-acting
beta2-agonist
|
|
|
|
|
Corticosteroid
Tablet or Syrup |
|
|
|
|
| |
LONG TERM TREATMENT PLAN
FOR MILD PERSISTENT ASTHMA
Name ________________ Date
___________ Spacer ____________
CLINICAL
CONDITION |
Baseline
Plan &
When asthma
is under control |
At
the FIRST
sign of a cold
Or mild attack |
For
rapidly
worsening asthma
(severe attack) |
When
there is
no cough or
wheeze for 2 months |
For
cough or wheeze with exercise |
Peak Flow
(% personal best) |
80% or above |
50 to 80% |
below 50% |
over 80%
for 2 months |
|
|
MEDICATION
Reliever:
Inhaled short-acting
beta2
-agonist
|
|
|
|
|
|
Controller
1) inhaled low dose
corticosteroid
or
|
|
|
|
|
| 2) nonsteroid |
|
|
|
|
Corticosteroid
Tablet or Syrup |
|
|
|
|
| |
LONG TERM TREATMENT PLAN FOR MODERATE
PERSISTENT ASTHMA
Name _____________ Date
___________ Spacer ____________
CLINICAL
CONDITION |
Baseline
Plan &
When asthma
is under control |
At
the FIRST
sign of a cold
Or mild attack |
For
rapidly
worsening asthma
(severe attack) |
When
there is
no cough or
wheeze for 2 months |
For
cough or wheeze with exercise |
Peak Flow
(% personal best) |
Baseline-60
to 80% Under control
-80% or above |
50 to 80% |
below 50% |
over 80%
for 2 months |
|
|
MEDICATION
Reliever:
Inhaled short-acting
beta2
-agonist
|
|
|
|
|
|
Controller
1) inhaled low dose
corticosteroid
and
|
|
|
|
|
|
2) Long-acting beta2-agonist
and
|
|
|
|
|
| 3) Antileukotriene |
|
|
|
|
Corticosteroid
Tablet or Syrup |
|
|
|
|
| |
LONG TERM TREATMENT PLAN FOR SEVERE PERSISTENT ASTHMA
Name ______________ Date
___________ Spacer ____________
CLINICAL
CONDITION |
Baseline
Plan &
When asthma is under control |
For
rapidly worsening asthma
(severe attack) |
When
there is no cough or wheeze for 2 months |
For cough
or wheeze with exercise |
Peak Flow
(% personal best) |
Baseline-below 60%Under control- 80% or above |
below 50% |
above 80% for 2 months |
|
|
MEDICATION
Reliever:
Inhaled short-acting
beta2-agonist
|
|
|
|
|
|
Controller:
1) Inhaled high dose Corticosteroid
and
2) Long-acting beta2-agonist
and
3) Antileukotriene
|
|
|
|
|
| |
|
|
|
| |
|
|
|
Corticosteroid
Tablet or Syrup |
|
|
|
|
| |